- PoliticsThe Week
- HealthAssociated Press
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. It is a setback for one of the most promising treatment approaches for COVID-19. President Donald Trump received a similar experimental, two-antibody drug from Regeneron Pharmaceuticals Inc. on an emergency basis when he was sickened with the coronavirus earlier this month.
The conservative attorney flipped the script in a satirical op-ed titled: "I believe in the president, now more than ever."
- U.S.USA TODAY Entertainment